Generic (Encorafenib) BRATODX

Inquire / Price
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    42c/Bottle
  • Strength
    75mg
  • Compositon
    Encorafenib
  • Treatment
    Metastatic melanoma & non-small cell lung cancer (NSCLC) with a BRAF V600E or V600K mutation
  • Form
    capsule
  • Brand
    BRATODX
  • Quantity Unit
    75mg*48c/Bottle
  • Manufacturer
    BIGBEAR Pharma,Laos PDR

About Encorafenib

Encorafenib is a medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.

Melanoma

Indicated in combination with binimetinib for unresectable or metastatic melanoma in patients with a BRAF V600E or V600K mutation, as detected by an FDA-approved test

450 mg PO qDay in combination with binimetinib

Continue until disease progression or unacceptable toxicity

See binimetinib drug monograph for recommended dosing information

Non-Small Cell Lung Cancer

Indicated in combination with binimetinib for unresectable or metastatic non-small cell lung cancer (NSCLC) in patients with a BRAF V600E mutation, as detected by an FDA-approved test

450 mg PO qDay in combination with binimetinib

Continue until disease progression or unacceptable toxicity

See binimetinib drug monograph for recommended dosing information

Metastatic Colorectal Cancer

Indicated in combination with cetuximab for metastatic colorectal cancer (CRC) in patients with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy

300 mg PO qDay in combination with cetuximab

Continue until disease progression or unacceptable toxicity

See cetuximab drug monograph for recommended dosing information


Link

Poster

Top